Veracyte Inc. logo

Veracyte Inc. (VCYT)

Market Open
21 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
23. 03
-0.48
-2.04%
$
1.98B Market Cap
- P/E Ratio
0% Div Yield
682,812 Volume
-0.74 Eps
$ 23.51
Previous Close
Day Range
22.96 23.78
Year Range
19.73 47.32
Want to track VCYT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 8 days
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.

Zacks | 8 months ago
Veracyte: Revolutionizing Noninvasive Cancer Diagnostics

Veracyte: Revolutionizing Noninvasive Cancer Diagnostics

In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).

Etftrends | 9 months ago
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Zacks | 10 months ago
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Zacks | 10 months ago
Here's Why Veracyte (VCYT) is a Strong Momentum Stock

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 10 months ago
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?

Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Zacks | 11 months ago
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 11 months ago
Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?

Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?

Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 11 months ago
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

Zacks | 11 months ago
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.

Benzinga | 11 months ago
Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Veracyte, Inc. (NASDAQ:VCYT ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Mason Carrico – Stephens, Inc. Yuko Oku – Morgan Stanley Maggie Boeye – William Blair Joseph Conway – Needham & Company Prashant Kota – Goldman Sachs Thomas DeBourcy – Nephron Research Operator Good day and thank you for standing by. Welcome to the Veracyte Second Quarter 2024 Financial Results Call.

Seekingalpha | 11 months ago
Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates

Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago.

Zacks | 11 months ago
Loading...
Load More